The government will soon take a call whether the two new Covid vaccines approved today, Corbevax and Covovax, may be used for booster doses -- an issue on which deliberations are on. The government had so far announced a third "precautionary dose" for health and frontline workers and senior citizens whose immunity is compromised. But a decision on booster dose for all -- as is happening in some nations with the surfacing of the highly contagious Omicron strain -- is yet to be taken.
Today, sources told NDTV that a decision is expected "within days".
If these vaccines are approved for a booster dose, a mix and match of vaccines is likely, since they both are different from Covishield and Covaxin, which use inactivated cold virus.
-
"High Inflation Is Like Tax On Everyone": RBI Governor At NDTV World Summit -
AI Agents To Outnumber Humans Soon? What Futurist Mike Walsh Told NDTV -
This Delhi Boy Has 3 Michelin Stars. His Heart Still Goes To Rajindar Da Dhaba -
AI Law In India Soon? What Ashwini Vaishnaw Said At NDTV World Summit -
'Need To Look At Next 10 Years': Bondada Chairperson To NDTV On Solar Energy -
World's 1st AI Actor Tilly Norwood Was Asked If She Knew Hindi. A Conversation Followed -
AI Law In India Soon? What Ashwini Vaishnaw Said At NDTV World Summit -
Iran's Supreme Leader's Representative Says India Can Play 'Big Role' In Middle East Peace -
Palestine Ambassador Accuses Netanyahu Of Supported Hamas, Blocking Two-State Solution -
Palestine Ambassador On Conflict With Israel: "It's A Genocide"
Sources said the two vaccines are also being considered for use of children.
The vaccines -- Serum Institute of India's Covovax and Biological E's Corbevax -- were authorised for "restricted use in emergency situation" earlier today.
The Corbevax is the country's first "RBD protein sub-unit vaccine" -- meaning it is made from a purified particle of the virus which triggers a strong immune response. The antibodies thus created target the spike protein of a virus, limiting its ability to latch onto body cells and penetrate them.
Covovax -- the Serum Institute's version of protein-based vaccine developed by Novavax -- also targets the spike protein on the surface of coronavirus.
In August 2020, Novavax had announced a license agreement with the Serum Institute for development and commercialisation of its NVX-CoV2373, in India and some low and middle-income countries.
The third shots of vaccine for healthcare, frontline workers and those above the age of 60 with comorbidities will begin in the country from January 10. Those aged between 15 and 18 years will get vaccinated from January 3.
More than 1.4 billion doses of vaccines have been administered in the county so far.
Track Latest News Live on NDTV.com and get news updates from India and around the world